Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Abstract

The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF… (More)
DOI: 10.1186/1476-8518-9-7

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Rodriguez2011SafetyIA, title={Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients}, author={Pedro Rodriguez and Elia Neninger and Beatriz Garc{\'i}a and Xitlally Popa and Carmen Elena Viada and Patricia Lorenzo Luaces and Gisela Gonz{\'a}lez and A. L. Lage and Enrique P{\'e}rez Montero and Tania Crombet}, booktitle={Journal of immune based therapies and vaccines}, year={2011} }